Drug Profile


Alternative Names: Azixa; EP-90745; MPC-6827; MX-128495; Veribulin

Latest Information Update: 30 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 28 Jun 2016 Immune Pharmaceuticals files for patent protection with the US Patent and Trademark Office for Verubulin in combination with immune checkpoint inhibitors for the treatment of cancer in USA
  • 28 Jun 2016 Preclinical trials in Colorectal cancer (Combination therapy) in USA (IV)
  • 12 Jan 2016 Verubulin is available for licensing as of 12 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top